Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)

Next Previous
X
Search
Trial Profile

FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gallium 68 PNT 6555 (Primary) ; Lutetium 177 PNT 6555 (Primary)
  • Indications Adenocarcinoma; Cholangiocarcinoma; Colorectal cancer; Malignant melanoma; Mouth neoplasm; Nasopharyngeal cancer; Oesophageal cancer; Oropharyngeal cancer; Pancreatic cancer; Pharyngeal neoplasms; Skin cancer; Soft tissue sarcoma; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; First in man
  • Acronyms FRONTIER
  • Sponsors Eli Lilly and Company; POINT Biopharma

    • Most Recent Events

    • 01 Nov 2023 Status changed from recruiting to active, no longer recruiting.
    • 06 Jun 2023 Trial design, presented at the 59th Annual Meeting of the American Society of Clinical Oncology
    • 25 May 2023 According to a POINT Biopharma media release, a Trial-in-Progress poster including background information, study design considerations, and a cohort enrollment status update will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top